Docetaxel

Name: Docetaxel
Brand: Selleck Chemicals
SKU: S1148
Rating: 5 (56 reviews)

For research use only. Not for use in humans.

Catalog No.S1148 Synonyms: RP56976, NSC 628503

56 publications

Molecular Weight(MW): 807.88

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

Selleck's Docetaxel has been cited by 56 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2018, 174(5):1200-1215

PubMed: 30100187 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0206

PubMed: 31113844 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Cancer Res, 2019, canres.0656.2019

PubMed: 31694904 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Cell Rep, 2019, 28(13):3367-3380

PubMed: 31553907 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0473-8

PubMed: 31857702 ( click the link to review the publication )

Int J Cancer, 2019, 145(7):1970-1981

PubMed: 30807643 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 31018595 ( click the link to review the publication )

Cell Death Discov, 2019, 0.30486111111

PubMed: 31583122 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):660

PubMed: 31506430 ( click the link to review the publication )

Arch Toxicol, 2019, 93(4):953-964

PubMed: 30863990 ( click the link to review the publication )

J Org Chem, 2019, 10.1021/acs.joc.9b02414

PubMed: 31858795 ( click the link to review the publication )

J Virol, 2019, 93(4)

PubMed: 30487274 ( click the link to review the publication )

Sci Rep, 2019, 9(1):16647

PubMed: 31719636 ( click the link to review the publication )

Mol Cell Endocrinol, 2019, 498:110585

PubMed: 31536779 ( click the link to review the publication )

Prostate, 2019, 79(11):1304-1315

PubMed: 31212367 ( click the link to review the publication )

Prostate, 2019, 79(9):1018-1031

PubMed: 31018021 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(3):551-559

PubMed: 30474758 ( click the link to review the publication )

Cancer Med, 2019, 10.1002/cam4.2764

PubMed: 31823522 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6421-6432

PubMed: 30087142 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2024-2033

PubMed: 29959202 ( click the link to review the publication )
Sci Rep, 2018, 8(1):14672

PubMed: 30279484 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

Biomed Pharmacother, 2018, 99:445-450

PubMed: 29665645 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1901-1909

PubMed: 29393407 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 81(2):255-267

PubMed: 29189915 ( click the link to review the publication )

Gene, 2018, 658:152-158

PubMed: 29518547 ( click the link to review the publication )

Int Urol Nephrol, 2018, 50(4):675-686

PubMed: 29460131 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(18):E3729-E3738

PubMed: 28416665 ( click the link to review the publication )

Cancer Res, 2017, 77(12):3268-3279

PubMed: 28400477 ( click the link to review the publication )

Oncogene, 2017, 36(14):1991-2001

PubMed: 27721412 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2552-2562

PubMed: 28847989 ( click the link to review the publication )

Mol Cancer Ther, 2017, 77(22):6282-6298

PubMed: 28424227 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(6):660-669

PubMed: 28209757 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Breast Cancer Res Treat, 2017, 165(3):531-543

PubMed: 28695300 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2302-2313

PubMed: 27474148 ( click the link to review the publication )

Prostate Cancer Prostatic Dis, 2016, 19(4):349-357

PubMed: 27349498 ( click the link to review the publication )

Prostate Cancer Prostatic Dis, 2016, 10.1038/pcan.2016.21

PubMed: 27349498 ( click the link to review the publication )

Int J Cancer, 2015, 136(9):2065-77

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:59

PubMed: 25902869 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.05.005

PubMed: ( click the link to review the publication )
PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27923-37

PubMed: 26314846 ( click the link to review the publication )

Oncotarget, 2015, 6(1):56-70

PubMed: 25474141 ( click the link to review the publication )

Oncogenesis, 2014, 3:e100

PubMed: 24752235 ( click the link to review the publication )

Mol Pharm, 2014, 11(7):2040-50

PubMed: 24779589 ( click the link to review the publication )

J Cell Mol Med, 2014, 18(5):811-23

PubMed: 24628949 ( click the link to review the publication )

J Nucl Med, 2013, 54(6):913-21

PubMed: 23564760 ( click the link to review the publication )

J Transl Med, 2013, 11:204

PubMed: 24004449 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

Targets

Microtubules ^[1]
(Cell-free assay)

In vitro

Docetaxel is a cytotoxic agent, especially for proliferating cells, which is related to its ability to promote the formation of microtubule bundles and induce sustained mitotic arrest, followed by apoptosis of mitotically arrested cells or permanent mitotic block. Docetaxel suppresses microtubule dynamic instability as well as tread-milling, resulting in the failure of chromosomes to segregate to the daughter cells, which in turn triggers premature exit from mitosis rather than a block at this phase of the cell cycle. ^[2] Docetaxel inhibits the clonogenic survival of Human cancer cell Hs746T (stomach), AGS (stomach), HeLa (cervix), CaSki (cervix), BxPC3 (pancreas), Capan-1 (pancreas) with IC50 of 1 nM, 1 nM, 0.3 nM, 0.3 nM, 0.3 nM and 0.3 nM respectively. ^[4] Docetaxel inhibits endothelial cell migration that does not affects microtubule gross morphology or inhibit cell proliferation, although they does produce more subtle effects on microtubule dynamics. Docetaxel inhibits HUVEC migration with an observed IC50 of 1 pM. HUVEC chemotaxis stimulated by either of two angiogenic factors, thymidine phosphorylase or VEGF, is inhibited by Docetaxel with IC 50 of 10 pM and is ablated at 1 nM. ^[7] Docetaxel induces human monocytes, but not RAW 264.7 murine macrophages, Prostaglandin H Synthase-2m (PGHS-2) expression. ^[8]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
HSC-3	NWDEPZhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH2xTHpKSzVyPUCuNFAxOTN{IN88US=>	MYHTRW5ITVJ?
5637	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXL0PYpLUUN3ME2wMlAxODF2MzFOwG0>	MmrnV2FPT0WU
HT-144	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHQTY1KSzVyPUCuNFAxOTV5IN88US=>	NGfIXHpUSU6JRWK=
NCI-H292	NWPVUWUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwMECwNVU6KM7:TR?=	NV3GOHlyW0GQR1XS
HCE-T	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnCTWM2OD1yLkCwNFE3OiEQvF2=	MnLUV2FPT0WU
ESS-1	M3Lxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDuTWM2OD1yLkCwNFE4QSEQvF2=	M2j6eXNCVkeHUh?=
D-566MG	M{XKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDKTWM2OD1yLkCwNFE5OiEQvF2=	MUXTRW5ITVJ?
CAL-62	NVXJVW9iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwMECwNVg2KM7:TR?=	MkDNV2FPT0WU
GT3TKB	M1XWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnCfIRKSzVyPUCuNFAxOjN{IN88US=>	MUjTRW5ITVJ?
HSC-4	M1PX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHrTWM2OD1yLkCwNFI{QSEQvF2=	NFXOSGlUSU6JRWK=
KOSC-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwMECwNlU2KM7:TR?=	MWrTRW5ITVJ?
NB14	M3LCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTTNZA6UUN3ME2wMlAxODJ4IN88US=>	M3HLfnNCVkeHUh?=
ES8	Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTBwMECwNlYh\|ryP	NY[2[3JHW0GQR1XS
BFTC-905	NUC5UotJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzNVXZKSzVyPUCuNFAxOjZ6IN88US=>	MXTTRW5ITVJ?
A498	NWPHSm1ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkK0TWM2OD1yLkCwNFI4QCEQvF2=	MVLTRW5ITVJ?
HO-1-N-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmGyTWM2OD1yLkCwNFI5OSEQvF2=	MVPTRW5ITVJ?
SF539	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTBwMECwN\|AzKM7:TR?=	M1\yTXNCVkeHUh?=
HuO-3N1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMECwN\|AzKM7:TR?=	NIDWV21USU6JRWK=
NCI-H510A	NYHIOXptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLVTWM2OD1yLkCwNFM{PiEQvF2=	NWnKcY55W0GQR1XS
CAL-27	NVPwdZNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjvXIJKSzVyPUCuNFAxOzN7IN88US=>	MUDTRW5ITVJ?
TE-8	NUmzb\|FlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwMECwN\|Y3KM7:TR?=	Mn;jV2FPT0WU
VA-ES-BJ	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwMECwN\|c2KM7:TR?=	M{nScnNCVkeHUh?=
RH-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHCOmtKSzVyPUCuNFAxOzh4IN88US=>	NXTnepRkW0GQR1XS
COLO-800	NUDudoNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{Luc2lEPTB;MD6wNFA{QDhizszN	NXTHRWtKW0GQR1XS
ES7	NEHTXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHobVZKSzVyPUCuNFAxOzh7IN88US=>	NUm2[o16W0GQR1XS
GAMG	MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7FTWM2OD1yLkCwNFQyPiEQvF2=	Mlj4V2FPT0WU
Ca9-22	NWGye3FMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIi4flRKSzVyPUCuNFAxPDJ\|IN88US=>	MoTGV2FPT0WU
SBC-1	NELPTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTyTJBRUUN3ME2wMlAxODR\|IN88US=>	NH6zNoxUSU6JRWK=
RPMI-7951	NXq3W2pwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TRcWlEPTB;MD6wNFA1PDhizszN	Mnv0V2FPT0WU
SW1710	NGrr[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HFT2lEPTB;MD6wNFA1PjZizszN	MlLmV2FPT0WU
HGC-27	NWX0RXZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwMECwOFcyKM7:TR?=	NYjJPZlOW0GQR1XS
MC-IXC	M1P0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDpXZBmUUN3ME2wMlAxODR5OTFOwG0>	MmDOV2FPT0WU
FTC-133	MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jDc2lEPTB;MD6wNFA1QDlizszN	M3fn[HNCVkeHUh?=
HT-1080	NV3ZeYxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzBUpdSUUN3ME2wMlAxODVyMTFOwG0>	MVnTRW5ITVJ?
NMC-G1	NETyOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTBwMECwOVE4KM7:TR?=	NHrZVWhUSU6JRWK=
GI-1	NE\ob4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfTTWM2OD1yLkCwNFUzQCEQvF2=	NWTuO5h2W0GQR1XS
CGTH-W-1	NGr4OJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Moj0TWM2OD1yLkCwNFU1OiEQvF2=	M1\rTnNCVkeHUh?=
A2058	M3XoN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwMECwOVQ1KM7:TR?=	NWHXWYQ6W0GQR1XS
ETK-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MluzTWM2OD1yLkCwNFU2QCEQvF2=	M2\C[HNCVkeHUh?=
NEC8	NFuwc5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrPUZJKSzVyPUCuNFAxPTZzIN88US=>	M{LRWXNCVkeHUh?=
TE-11	MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTBwMECwOVY6KM7:TR?=	MmSyV2FPT0WU
NCI-H720	M3TveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfSbopTUUN3ME2wMlAxODV6IN88US=>	NHXtNmNUSU6JRWK=
PSN1	M1HiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWW4SJVnUUN3ME2wMlAxODV6MTFOwG0>	M4fCeHNCVkeHUh?=
SW780	NXnGVlR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\LZWxKSzVyPUCuNFAxPTh5IN88US=>	MlzhV2FPT0WU
8-MG-BA	Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwMECwOVg6KM7:TR?=	NHvGXXFUSU6JRWK=
EC-GI-10	M{LqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFKzN2xKSzVyPUCuNFAxPTl{IN88US=>	M123bHNCVkeHUh?=
SJSA-1	MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXKUHExUUN3ME2wMlAxODZzNTFOwG0>	NGrGdopUSU6JRWK=
639-V	NVfwWpdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7PdVV7UUN3ME2wMlAxODZ2NzFOwG0>	MVvTRW5ITVJ?
PFSK-1	NX\zRmJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwMECwOlU4KM7:TR?=	Mn7OV2FPT0WU
DMS-273	NYH6S3YxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXCenpoUUN3ME2wMlAxODZ5NDFOwG0>	MYrTRW5ITVJ?
TE-9	MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwMECwOlc3KM7:TR?=	M336enNCVkeHUh?=
SCC-25	M3fpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljpTWM2OD1yLkCwNFY5KM7:TR?=	MlX2V2FPT0WU
PA-1	NWTadZVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2G2T2lEPTB;MD6wNFA3QDdizszN	M1\LbnNCVkeHUh?=
MHH-ES-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoD2TWM2OD1yLkCwNFch\|ryP	MnLpV2FPT0WU
Daoy	NVXNTlFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTnTWM2OD1yLkCwNFch\|ryP	NXrqdW5IW0GQR1XS
G-402	MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vM[GlEPTB;MD6wNFA4ODZizszN	MmPxV2FPT0WU
YKG-1	NEfz[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\4TWM2OD1yLkCwNFcxPyEQvF2=	MmrtV2FPT0WU
Ca-Ski	M4K1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVn6U49LUUN3ME2wMlAxODd{ODFOwG0>	NYfONYx3W0GQR1XS
CHP-212	NFz3WI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33CfGlEPTB;MD6wNFA4OyEQvF2=	Mk\KV2FPT0WU
SCC-4	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwMECwO\|M6KM7:TR?=	NHfpfWJUSU6JRWK=
EW-3	NXfYcZdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17OSGlEPTB;MD6wNFA4PDVizszN	Mon2V2FPT0WU
P12-ICHIKAWA	NIPEeJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DKVWlEPTB;MD6wNFA4PDVizszN	NH;3S3ZUSU6JRWK=
HSC-2	M2DZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUf2eIE1UUN3ME2wMlAxODd3NTFOwG0>	MnPQV2FPT0WU
HN	M2[4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fjOmlEPTB;MD6wNFA4PThizszN	MkfrV2FPT0WU
LXF-289	M1jKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwMECwO\|U5KM7:TR?=	MYPTRW5ITVJ?
ES1	NUDod5BET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwMECwO\|ch\|ryP	M1y4SXNCVkeHUh?=
NTERA-S-cl-D1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojOTWM2OD1yLkCwNFc4OyEQvF2=	M{H3e3NCVkeHUh?=
K5	NF;ocoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\hTWM2OD1yLkCwNFc4QCEQvF2=	NXiySFZ{W0GQR1XS
HOS	NV3yU\|AxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPaN\|lKSzVyPUCuNFAxPzh{IN88US=>	NWGxRnloW0GQR1XS
YH-13	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLCTWM2OD1yLkCwNFc6OSEQvF2=	NUWw[m02W0GQR1XS
SW954	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jxemlEPTB;MD6wNFA5OjNizszN	NYHjT2prW0GQR1XS
KYSE-510	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NES4enZKSzVyPUCuNFAxQDRizszN	MWLTRW5ITVJ?
8505C	M3PRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwMECwPFU1KM7:TR?=	M4ftfnNCVkeHUh?=
A549	NGjaemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jrPWlEPTB;MD6wNFA5QDJizszN	NYrXbYt{W0GQR1XS
Detroit562	NH3jXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rLemlEPTB;MD6wNFA6ODJizszN	NWXEb2NqW0GQR1XS
ES5	MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\iN5poUUN3ME2wMlAxODlzIN88US=>	M2\LWHNCVkeHUh?=
KYSE-140	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfUTWM2OD1yLkCwNFk{OyEQvF2=	NI[xRVVUSU6JRWK=
GMS-10	NGDhOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU[wZ4tQUUN3ME2wMlAxODl2MTFOwG0>	NVXuSJVCW0GQR1XS
D-263MG	NH:ydFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XVVGlEPTB;MD6wNFA6PDdizszN	M1T6Z3NCVkeHUh?=
BCPAP	NHzYS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fJeGlEPTB;MD6wNFA6PDdizszN	MYnTRW5ITVJ?
CHL-1	MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrPSmZKUUN3ME2wMlAxODl3ODFOwG0>	Mk\NV2FPT0WU
RKO	NH7jc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;0ZZZNUUN3ME2wMlAxODl6OTFOwG0>	NXfwR\|FYW0GQR1XS
SW48	NIPYS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnjZYV5UUN3ME2wMlAxOTBzIN88US=>	NGq2enRUSU6JRWK=
BPH-1	M3qwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;w[mlEPTB;MD6wNFExOiEQvF2=	MWDTRW5ITVJ?
EFO-27	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jLNmlEPTB;MD6wNFExOiEQvF2=	NI\IcYNUSU6JRWK=
CAL-33	NX7RSmtYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXxRm1KSzVyPUCuNFAyODRizszN	MojyV2FPT0WU
NCI-H1792	NHnXdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrHTWM2OD1yLkCwNVA1KM7:TR?=	M1;xVXNCVkeHUh?=
BB30-HNC	MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HoU2lEPTB;MD6wNFExPSEQvF2=	MWjTRW5ITVJ?
VM-CUB-1	M1f4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV2yblV1UUN3ME2wMlAxOTB3IN88US=>	M2DB[HNCVkeHUh?=
TE-5	M1Ls[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvQTWM2OD1yLkCwNVA3KM7:TR?=	MWPTRW5ITVJ?
NB13	MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn65TWM2OD1yLkCwNVA4KM7:TR?=	MUTTRW5ITVJ?
NBsusSR	M1T4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfrU4hFUUN3ME2wMlAxOTFizszN	Mn3uV2FPT0WU
LNCaP-Clone-FGC	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMECxNUDPxE1?	NHXnVIVUSU6JRWK=
EPLC-272H	M2X2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMECxNVEh\|ryP	NWXpT4x3W0GQR1XS
KNS-62	MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrPS29KSzVyPUCuNFAyOTJizszN	NFnkS\|hUSU6JRWK=
RERF-LC-MS	NHj6OFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\2TWM2OD1yLkCwNVE{KM7:TR?=	MlSyV2FPT0WU
LOXIMVI	NWjteIJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17TcGlEPTB;MD6wNFEyPiEQvF2=	NHrCNFhUSU6JRWK=
KINGS-1	NXzXRY53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4[xcmlEPTB;MD6wNFEyPyEQvF2=	NYTJUlR[W0GQR1XS
T98G	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PZNWlEPTB;MD6wNFEyPyEQvF2=	Ml\uV2FPT0WU
HCC1806	M1m2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwMECxNVgh\|ryP	NVvYd4dRW0GQR1XS
MZ1-PC	Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;QdnRNUUN3ME2wMlAxOTF6IN88US=>	M33PRXNCVkeHUh?=
RT-112	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXFUnpKSzVyPUCuNFAyOTlizszN	MmPJV2FPT0WU
LK-2	NH7mcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7jTWM2OD1yLkCwNVIyKM7:TR?=	M4DDNnNCVkeHUh?=
A375	M4D4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3QTWM2OD1yLkCwNVIyKM7:TR?=	MVnTRW5ITVJ?
SF268	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfnTWM2OD1yLkCwNVIyKM7:TR?=	NXzKb3NGW0GQR1XS
H9	M4i1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmq5TWM2OD1yLkCwNVI1KM7:TR?=	MXLTRW5ITVJ?
KYSE-410	MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXT4e3k3UUN3ME2wMlAxOTJ2IN88US=>	MYHTRW5ITVJ?
G-401	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmG0TWM2OD1yLkCwNVI4KM7:TR?=	MYHTRW5ITVJ?
SW982	NF7tfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\MfHBKSzVyPUCuNFAyOjdizszN	NWPoWHVVW0GQR1XS
D-423MG	MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2izeGlEPTB;MD6wNFE{KM7:TR?=	MXLTRW5ITVJ?
CAMA-1	NW\YXlBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwMECxN\|Eh\|ryP	NUPmPYRYW0GQR1XS
SCC-9	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHMNlhKSzVyPUCuNFAyOzJizszN	M4LDOHNCVkeHUh?=
SAS	NFXJd3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwMECxN\|Qh\|ryP	NHPSSYZUSU6JRWK=
KYSE-180	M{DsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3qSJpvUUN3ME2wMlAxOTN3IN88US=>	M{L5NHNCVkeHUh?=
EW-16	NVHrcIJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjrZ\|I5UUN3ME2wMlAxOTN3IN88US=>	MoG0V2FPT0WU
HD-MY-Z	NInxZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnn5TWM2OD1yLkCwNVQyKM7:TR?=	M2nQdHNCVkeHUh?=
KYSE-450	MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4D5fGlEPTB;MD6wNFE1OyEQvF2=	NVvYb\|dCW0GQR1XS
LCLC-97TM1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M364WWlEPTB;MD6wNFE1PCEQvF2=	M1qyR3NCVkeHUh?=
KS-1	NYPjWVRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwMECxOFQh\|ryP	MnmzV2FPT0WU
TI-73	MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zKe2lEPTB;MD6wNFE1PCEQvF2=	NGPIRmlUSU6JRWK=
A427	NVO2Vm5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwMECxOFgh\|ryP	M4LDenNCVkeHUh?=
LB831-BLC	NGPIVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rGW2lEPTB;MD6wNFE1QCEQvF2=	MVPTRW5ITVJ?
MG-63	NYXZO\|NHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwMECxOVEh\|ryP	M4TWZ3NCVkeHUh?=
PANC-03-27	NUK0W3NFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMECxOVQh\|ryP	NHrueYNUSU6JRWK=
23132-87	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4qzcGlEPTB;MD6wNFE2PSEQvF2=	NFG0fYFUSU6JRWK=
ES4	M3;uN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWr0XnJGUUN3ME2wMlAxOTV3IN88US=>	NX33OZpxW0GQR1XS
KP-4	NH7TXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LlfWlEPTB;MD6wNFE2PiEQvF2=	M2\IbXNCVkeHUh?=
NCI-H1703	Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHSTWM2OD1yLkCwNVU4KM7:TR?=	Mln0V2FPT0WU
MCF7	M4XKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfoRW9KSzVyPUCuNFAyPjFizszN	MXvTRW5ITVJ?
A172	MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFP5ZpJKSzVyPUCuNFAyPjNizszN	NYPNelFJW0GQR1XS
CAL-39	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\5cFVKSzVyPUCuNFAyPjNizszN	MlrGV2FPT0WU
Saos-2	NVjjOXhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFSxOm5KSzVyPUCuNFAyPjhizszN	NHjTfpFUSU6JRWK=
EW-11	MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnRb\|JKSzVyPUCuNFAyPjlizszN	NWGxfm9RW0GQR1XS
D-336MG	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13JXmlEPTB;MD6wNFE3QSEQvF2=	MWDTRW5ITVJ?
SW13	M{i4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7vTWM2OD1yLkCwNVY6KM7:TR?=	MkHTV2FPT0WU
ME-180	NFP6XXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTCTWM2OD1yLkCwNVY6KM7:TR?=	NXfO[ow3W0GQR1XS
SK-MEL-2	NHvxUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMECxO{DPxE1?	Mor5V2FPT0WU
697	MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwMECxO\|Ih\|ryP	NYXERYloW0GQR1XS
D-247MG	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\ZNoFSUUN3ME2wMlAxOTd\|IN88US=>	MUfTRW5ITVJ?
EoL-1-cell	NEHEdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXRO2VKSzVyPUCuNFAyPzNizszN	MUnTRW5ITVJ?
MV-4-11	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TYR2lEPTB;MD6wNFE4PCEQvF2=	MW\TRW5ITVJ?
U-2-OS	NGHsdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwMECxO\|Uh\|ryP	NGmzb2tUSU6JRWK=
NCI-H526	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVT2bnhsUUN3ME2wMlAxOTd4IN88US=>	NEHpfWRUSU6JRWK=
SK-NEP-1	NV\ZcGdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfNUIFrUUN3ME2wMlAxOTd4IN88US=>	MV3TRW5ITVJ?
DB	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjBVWVsUUN3ME2wMlAxOTd6IN88US=>	NISycIJUSU6JRWK=
GCT	NHq1S4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPhTWM2OD1yLkCwNVgh\|ryP	M4\pUnNCVkeHUh?=
HCT-116	NXPqXpUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfLTWM2OD1yLkCwNVgyKM7:TR?=	M322Z3NCVkeHUh?=
AU565	Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3XTo5KSzVyPUCuNFAyQDFizszN	M4Dvb3NCVkeHUh?=
KALS-1	M1LXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LlNmlEPTB;MD6wNFE5OSEQvF2=	NFnF[ZZUSU6JRWK=
C2BBe1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXZTWM2OD1yLkCwNVgzKM7:TR?=	MkW1V2FPT0WU
Becker	M3f3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwMECxPFMh\|ryP	NEG2fHVUSU6JRWK=
647-V	M4GyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTmTWM2OD1yLkCwNVg1KM7:TR?=	NVLjcFRNW0GQR1XS
NCI-H2122	NYT2dZlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{KzdmlEPTB;MD6wNFE5PCEQvF2=	MnrFV2FPT0WU
SBC-5	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TRb2lEPTB;MD6wNFE5PyEQvF2=	M{e0OXNCVkeHUh?=
NB17	NVflN2VNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfWTWM2OD1yLkCwNVg6KM7:TR?=	NUj1WGJUW0GQR1XS
MHH-PREB-1	NUW2Z2xKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwMECxPFkh\|ryP	NXPoVopxW0GQR1XS
M14	Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLNTWM2OD1yLkCwNVkyKM7:TR?=	M3vzeHNCVkeHUh?=
NCI-H1048	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\sdmlEPTB;MD6wNFE6OiEQvF2=	NHPjRodUSU6JRWK=
CTB-1	NFnPPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{W3XWlEPTB;MD6wNFE6OiEQvF2=	M4CweHNCVkeHUh?=
SK-PN-DW	MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwMECxPVQh\|ryP	NUj4d5dFW0GQR1XS
H4	NYPlT2RET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NImyV5dKSzVyPUCuNFAyQTZizszN	MWjTRW5ITVJ?
NCI-SNU-1	Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWj1SJBpUUN3ME2wMlAxOTl5IN88US=>	MkS5V2FPT0WU
M059J	M4S5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXW5OoZHUUN3ME2wMlAxOTl6IN88US=>	M1HxWXNCVkeHUh?=
OVCAR-5	M1zwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjDXI9KSzVyPUCuNFAyQTlizszN	MVnTRW5ITVJ?
SK-MEL-28	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37H[mlEPTB;MD6wNFIxOyEQvF2=	NU\4OnBGW0GQR1XS
PC-14	MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmW2TWM2OD1yLkCwNlA6KM7:TR?=	NGfBXYtUSU6JRWK=
OVCAR-8	NHXr[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPMe5c5UUN3ME2wMlAxOjF{IN88US=>	NHfW[FJUSU6JRWK=
BB49-HNC	NXXNWFFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETFUYJKSzVyPUCuNFAzOTJizszN	M1f4eHNCVkeHUh?=
EFM-19	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{f3RWlEPTB;MD6wNFIyPSEQvF2=	MmHMV2FPT0WU
BHY	NY\nW5NyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMECyNVYh\|ryP	NIfGUnFUSU6JRWK=
SW756	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HTU2lEPTB;MD6wNFIyPiEQvF2=	MlTTV2FPT0WU
TE-1	M4nsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fjPGlEPTB;MD6wNFIyPiEQvF2=	NX\RV\|QxW0GQR1XS
NCI-H2452	NYW3W\|BGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMECyNVYh\|ryP	MU\TRW5ITVJ?
NCI-H1581	Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13PU2lEPTB;MD6wNFIyPyEQvF2=	MlTYV2FPT0WU
COR-L23	NWnt[GFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwMECyNkDPxE1?	MXzTRW5ITVJ?
RXF393	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nmT2lEPTB;MD6wNFIzOiEQvF2=	M2Hl[nNCVkeHUh?=
BFTC-909	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwMECyNlUh\|ryP	NX;4blFyW0GQR1XS
IST-MEL1	NG\ZW\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwMECyNlUh\|ryP	MXTTRW5ITVJ?
NCI-H650	NILkTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfwSYJwUUN3ME2wMlAxOjJ3IN88US=>	MXrTRW5ITVJ?
SK-UT-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnrTWM2OD1yLkCwNlI3KM7:TR?=	NFr1RplUSU6JRWK=
GOTO	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwMECyNlch\|ryP	Mmi2V2FPT0WU
TYK-nu	MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPZVY52UUN3ME2wMlAxOjN{IN88US=>	MWDTRW5ITVJ?
JVM-3	M3jRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFX0XJZKSzVyPUCuNFAzOzNizszN	M1ftSXNCVkeHUh?=
SK-MES-1	NHHNSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjI[\|Y{UUN3ME2wMlAxOjN\|IN88US=>	NHriPWNUSU6JRWK=
SK-HEP-1	NUHiS3BRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwMECyN\|Qh\|ryP	MnPVV2FPT0WU
J-RT3-T3-5	NHPnfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLBfJNEUUN3ME2wMlAxOjN3IN88US=>	NUK1bHpDW0GQR1XS
A673	M3u1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHqXIdJUUN3ME2wMlAxOjN3IN88US=>	MV7TRW5ITVJ?
NCI-H446	M3v0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXf6dI1nUUN3ME2wMlAxOjR\|IN88US=>	MXvTRW5ITVJ?
RPMI-2650	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTBwMECyOFYh\|ryP	MlHZV2FPT0WU
HCE-4	NF3CVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwMECyOFch\|ryP	NX7rO4VmW0GQR1XS
KGN	Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH63Z3VKSzVyPUCuNFAzPDdizszN	NHnCXWRUSU6JRWK=
U251	NXLZVWVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rvc2lEPTB;MD6wNFI2KM7:TR?=	MnLKV2FPT0WU
BxPC-3	M4TPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTBwMECyOVEh\|ryP	NYf4VZd3W0GQR1XS
VMRC-RCZ	M4XrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzPTWM2OD1yLkCwNlUzKM7:TR?=	NH76W5ZUSU6JRWK=
TE-10	NHPYNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XJSGlEPTB;MD6wNFI2PCEQvF2=	M1XCSnNCVkeHUh?=
OC-314	NGL6XplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\GWWlEPTB;MD6wNFI2PiEQvF2=	MUHTRW5ITVJ?
NCI-H1437	MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml64TWM2OD1yLkCwNlYh\|ryP	M{f4VHNCVkeHUh?=
SNU-387	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nMb2lEPTB;MD6wNFI3OSEQvF2=	M1fxOXNCVkeHUh?=
A388	M2LuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwMECyOlUh\|ryP	M17j[nNCVkeHUh?=
C-33-A	NFXjN3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTGeIhJUUN3ME2wMlAxOjZ4IN88US=>	NYrYTGVjW0GQR1XS
CAL-51	MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMECyO\|Eh\|ryP	MYrTRW5ITVJ?
Hs-578-T	NHPNbFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwMECyO\|Ih\|ryP	NIHHdHdUSU6JRWK=
MDA-MB-415	NXrIS4t2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7DTWM2OD1yLkCwNlc1KM7:TR?=	MWPTRW5ITVJ?
SW1417	MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXy3XpUzUUN3ME2wMlAxOjd4IN88US=>	MVPTRW5ITVJ?
HCC70	M163XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vRTmlEPTB;MD6wNFI4PyEQvF2=	M1LtWXNCVkeHUh?=
ES3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXsUlBKSzVyPUCuNFAzPzdizszN	NWL6T2lOW0GQR1XS
KYSE-270	M4Xnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrxXI5FUUN3ME2wMlAxOjd6IN88US=>	M2rnPXNCVkeHUh?=
HT-29	MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYi4c3pZUUN3ME2wMlAxOjhizszN	MVfTRW5ITVJ?
MDA-MB-361	NULYUGR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7MPGpKSzVyPUCuNFAzQDFizszN	NYr2dJB4W0GQR1XS
RPMI-8866	Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwMECyPFEh\|ryP	Mk\HV2FPT0WU
JEG-3	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fuV2lEPTB;MD6wNFI5OiEQvF2=	NYG1dIZJW0GQR1XS
HT-3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorNTWM2OD1yLkCwNlgzKM7:TR?=	NG\4WW9USU6JRWK=
HTC-C3	M3jiSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrJ[FFKSzVyPUCuNFAzQDVizszN	NGOwNINUSU6JRWK=
NCI-H209	M3fENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mle5TWM2OD1yLkCwNlg3KM7:TR?=	Mmn6V2FPT0WU
SKG-IIIa	NIXuPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLZOGFDUUN3ME2wMlAxOjh4IN88US=>	MoPlV2FPT0WU
SW962	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHoTWM2OD1yLkCwNlk{KM7:TR?=	NWS1cnltW0GQR1XS
LCLC-103H	Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\XTWM2OD1yLkCwNlk{KM7:TR?=	NVqzflIyW0GQR1XS
DOK	NXfUcW1pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\u[YxXUUN3ME2wMlAxOjl2IN88US=>	NFi4dpFUSU6JRWK=
SW1088	M{nXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnZcGdKSzVyPUCuNFAzQTVizszN	MlzmV2FPT0WU
GP5d	MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXVRnNuUUN3ME2wMlAxOjl4IN88US=>	NX7XboR1W0GQR1XS
EW-1	MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3OTWM2OD1yLkCwNlk5KM7:TR?=	MVnTRW5ITVJ?
CP66-MEL	MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7yeZBZUUN3ME2wMlAxOyEQvF2=	NXnqTGlDW0GQR1XS
DEL	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jRcWlEPTB;MD6wNFMxOSEQvF2=	MmqyV2FPT0WU
DU-4475	M3;jZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPHTWM2OD1yLkCwN\|AzKM7:TR?=	M{LPW3NCVkeHUh?=
HEC-1	NFPnZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHy[nlKSzVyPUCuNFA{ODNizszN	M{T2SXNCVkeHUh?=
U031	MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXVUWtNUUN3ME2wMlAxOzB5IN88US=>	MlqwV2FPT0WU
BB65-RCC	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;CTWM2OD1yLkCwN\|A5KM7:TR?=	M3nBWXNCVkeHUh?=
NUGC-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwMECzNFgh\|ryP	M4H4bnNCVkeHUh?=
IST-SL1	MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWW5bpE6UUN3ME2wMlAxOzF{IN88US=>	MUfTRW5ITVJ?
LS-411N	NXHlRWlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwMECzNVQh\|ryP	NUHnfZRsW0GQR1XS
22RV1	NYTvdJdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3vdYVWUUN3ME2wMlAxOzF3IN88US=>	M4G5UHNCVkeHUh?=
MKN28	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHqTWM2OD1yLkCwN\|E4KM7:TR?=	MnfLV2FPT0WU
ONS-76	MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMECzNlIh\|ryP	MV7TRW5ITVJ?
SH-4	NFfvN5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDjeWRlUUN3ME2wMlAxOzJ{IN88US=>	NV;VPYVvW0GQR1XS
MIA-PaCa-2	MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXoTWM2OD1yLkCwN\|I1KM7:TR?=	NXztR4ZnW0GQR1XS
CaR-1	MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPOTWM2OD1yLkCwN\|I4KM7:TR?=	NWXzdFlsW0GQR1XS
AGS	M3G3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnrOIxKSzVyPUCuNFA{OjhizszN	MlrUV2FPT0WU
SF126	NVz1[FYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjDNYhKSzVyPUCuNFA{OjlizszN	NEn3T4NUSU6JRWK=
UACC-62	M1zx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfhNmFKSzVyPUCuNFA{OyEQvF2=	NH;LOZlUSU6JRWK=
NCI-H28	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLFfW5KSzVyPUCuNFA{OzRizszN	NIXUZnlUSU6JRWK=
A2780	NVTyOVdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMECzN\|Uh\|ryP	NYfZXZlxW0GQR1XS
CTV-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7xOmxKSzVyPUCuNFA{OzdizszN	NWfiU2xmW0GQR1XS
LC-2-ad	NEHPNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYT4S\|hEUUN3ME2wMlAxOzRizszN	NXrWdpJKW0GQR1XS
NCI-H1770	NH3U[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIj5flNKSzVyPUCuNFA{PDJizszN	M{ToXHNCVkeHUh?=
HuO9	NY\1XFhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPlTWM2OD1yLkCwN\|Q3KM7:TR?=	NIHQPZVUSU6JRWK=
U-266	NFKwS\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nRd2lEPTB;MD6wNFM1QCEQvF2=	NWfndWxjW0GQR1XS
MLMA	M2\6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwMECzOVUh\|ryP	NFH1RnpUSU6JRWK=
U-87-MG	M{X5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\CWXhKSzVyPUCuNFA{PTVizszN	M4j0R3NCVkeHUh?=
GI-ME-N	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjOTWM2OD1yLkCwN\|U5KM7:TR?=	NH7IfnVUSU6JRWK=
HL-60	MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fudGlEPTB;MD6wNFM2QSEQvF2=	MYrTRW5ITVJ?
EGI-1	M{DKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\uVnJKSzVyPUCuNFA{PjJizszN	M{OzUnNCVkeHUh?=
NCI-H23	M4P0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwMECzOlQh\|ryP	Mkn6V2FPT0WU
NCI-H226	Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\FeINDUUN3ME2wMlAxOzZ6IN88US=>	MlPTV2FPT0WU
NCI-H520	MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwMECzO\|Ih\|ryP	MnXRV2FPT0WU
L-363	Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlP2TWM2OD1yLkCwN\|c3KM7:TR?=	Mkj4V2FPT0WU
CAL-12T	M33JNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwMECzO\|Yh\|ryP	MmHBV2FPT0WU
BT-20	NFzoTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvHVVM6UUN3ME2wMlAxOzd4IN88US=>	NYTNT5o6W0GQR1XS
SNB75	NHjZbY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVr4TXVvUUN3ME2wMlAxOzhzIN88US=>	MU\TRW5ITVJ?
A4-Fuk	NXezWYZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvlTWM2OD1yLkCwN\|kh\|ryP	Mkn0V2FPT0WU
BE-13	NIDTfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFntT3ZKSzVyPUCuNFA{QTNizszN	MlPnV2FPT0WU
NCI-H1395	NHPieG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTS[YxKSzVyPUCuNFA{QTZizszN	M2jIb3NCVkeHUh?=
SW620	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXnbJZKSzVyPUCuNFA{QTdizszN	MXLTRW5ITVJ?
KNS-81-FD	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVeycW1WUUN3ME2wMlAxOzl7IN88US=>	NH\QSXZUSU6JRWK=
RD	NF3LRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwMEC0JO69VQ>?	M1ewZXNCVkeHUh?=
HLE	NHToSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjw[mxVUUN3ME2wMlAxPDB3IN88US=>	NXTrXFk2W0GQR1XS
OVCAR-3	NXPjUok5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoP5TWM2OD1yLkCwOFA4KM7:TR?=	NWXMdFdCW0GQR1XS
KM12	MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXoTWM2OD1yLkCwOFA5KM7:TR?=	NUnsOllSW0GQR1XS
HCC2998	M3P0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDXTWM2OD1yLkCwOFA5KM7:TR?=	MYTTRW5ITVJ?
D-502MG	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PTOmlEPTB;MD6wNFQyKM7:TR?=	M2PiRXNCVkeHUh?=
KNS-42	M1e2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILndoJKSzVyPUCuNFA1OTJizszN	NHnGR2tUSU6JRWK=
LS-123	NVLFO4ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjuXZViUUN3ME2wMlAxPDJ3IN88US=>	NGLidndUSU6JRWK=
SiHa	NY\Td5psT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPwNnFKSzVyPUCuNFA1OyEQvF2=	MmDFV2FPT0WU
T47D	NIf5TZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFv0W45KSzVyPUCuNFA1OzFizszN	NHq5NFJUSU6JRWK=
EW-24	MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{[xbGlEPTB;MD6wNFQ{OyEQvF2=	NWHDc2llW0GQR1XS
CAL-120	M1PtWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;1TWM2OD1yLkCwOFM2KM7:TR?=	MkfPV2FPT0WU
JAR	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXzboZrUUN3ME2wMlAxPDN5IN88US=>	MWnTRW5ITVJ?
QIMR-WIL	NIHsU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwMEC0N\|gh\|ryP	MnHqV2FPT0WU
OCUB-M	M33mVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1i0PWlEPTB;MD6wNFQ{QCEQvF2=	NXq0PYlbW0GQR1XS
Calu-6	MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zmemlEPTB;MD6wNFQ1PyEQvF2=	NFW0e2VUSU6JRWK=
MDA-MB-453	NHHBdIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwMEC0OVEh\|ryP	NXfGO21EW0GQR1XS
MKN45	MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3q2T2lEPTB;MD6wNFQ2OyEQvF2=	NWPxVm12W0GQR1XS
ECC10	Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7ye2JQUUN3ME2wMlAxPDZizszN	MX7TRW5ITVJ?
RVH-421	MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\uTWM2OD1yLkCwOFYyKM7:TR?=	Mn74V2FPT0WU
TGBC11TKB	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HwVmlEPTB;MD6wNFQ3QSEQvF2=	NIPBR4FUSU6JRWK=
MOLT-4	MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwMEC0O\|Eh\|ryP	NYTnWYt4W0GQR1XS
LN-405	NYLse45nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1f0OWlEPTB;MD6wNFQ5OiEQvF2=	NUHyV4tTW0GQR1XS
S-117	NViw[2I2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrKTWM2OD1yLkCwOFg3KM7:TR?=	M{PUd3NCVkeHUh?=
RPMI-8226	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMEC0PVch\|ryP	NXq4NpJvW0GQR1XS
KYSE-150	NUTrRo57T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{joPGlEPTB;MD6wNFQ6QSEQvF2=	Mmn0V2FPT0WU
NCI-H1666	NY[xS3pJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVT4T5llUUN3ME2wMlAxPTB3IN88US=>	NHrLO3pUSU6JRWK=
Mewo	MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jFdWlEPTB;MD6wNFUxPSEQvF2=	Mk\uV2FPT0WU
AN3-CA	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3ThPGlEPTB;MD6wNFUxPyEQvF2=	MWLTRW5ITVJ?
COLO-680N	NF;1Z2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7EV3ZKSzVyPUCuNFA2ODhizszN	MlflV2FPT0WU
FADU	M3r5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\1fHhKSzVyPUCuNFA2OSEQvF2=	NFq4flRUSU6JRWK=
GB-1	M3XqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwMEC1NVEh\|ryP	M2TkcHNCVkeHUh?=
KASUMI-1	MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjJUnk{UUN3ME2wMlAxPTFzIN88US=>	MnTiV2FPT0WU
NOMO-1	NWXaNWh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDyTmFKSzVyPUCuNFA2OTNizszN	NVPJdlNMW0GQR1XS
BV-173	NITlUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnH3TWM2OD1yLkCwOVMh\|ryP	Mnu5V2FPT0WU
RO82-W-1	NVPtT3FnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlP1TWM2OD1yLkCwOVMyKM7:TR?=	MX7TRW5ITVJ?
LB2241-RCC	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPYXIFrUUN3ME2wMlAxPTNzIN88US=>	MknYV2FPT0WU
NCI-H2170	NFPLe2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTXdIRKSzVyPUCuNFA2OzVizszN	M2rr[3NCVkeHUh?=
SK-N-AS	NWTUV\|ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvwSoJKSzVyPUCuNFA2OzVizszN	NGPCTGZUSU6JRWK=
NCI-H1651	MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwMEC1OEDPxE1?	NUn2VFZuW0GQR1XS
NCI-SNU-5	MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\yUGlEPTB;MD6wNFU1PSEQvF2=	M2jUZXNCVkeHUh?=
SN12C	MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzuTWM2OD1yLkCwOVUh\|ryP	MYrTRW5ITVJ?
KY821	M2DmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWm2OlA1UUN3ME2wMlAxPTVzIN88US=>	NEWycnVUSU6JRWK=
SW1573	MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTCO\|NKSzVyPUCuNFA2PTRizszN	M3j1XnNCVkeHUh?=
OE19	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXnTWM2OD1yLkCwOVU6KM7:TR?=	MV7TRW5ITVJ?
MPP-89	M{jXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zYbmlEPTB;MD6wNFU3PyEQvF2=	MVnTRW5ITVJ?
HuCCT1	M2nyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHDSmhnUUN3ME2wMlAxPTZ6IN88US=>	MXTTRW5ITVJ?
SW1783	Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jhcGlEPTB;MD6wNFU4KM7:TR?=	NYfsU5R6W0GQR1XS
8305C	M{W5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwMEC1O\|Yh\|ryP	MXHTRW5ITVJ?
OVCAR-4	NVOzfFQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXntS3FIUUN3ME2wMlAxPTh4IN88US=>	M2fMUnNCVkeHUh?=
MMAC-SF	NFr6dJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLhU40{UUN3ME2wMlAxPTh4IN88US=>	MVPTRW5ITVJ?
COLO-824	M4DhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnZe25YUUN3ME2wMlAxPTlizszN	NWXkflBrW0GQR1XS
HCC38	M332Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMEC2JO69VQ>?	NGfPPVlUSU6JRWK=
NCI-H1648	NE\yUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrSTWM2OD1yLkCwOlAyKM7:TR?=	MlfRV2FPT0WU
NCI-H1573	NXm4S4ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLZOYNxUUN3ME2wMlAxPjB5IN88US=>	NVPrTJI{W0GQR1XS
MFM-223	MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorQTWM2OD1yLkCwOlE3KM7:TR?=	M3nhN3NCVkeHUh?=
NCI-H810	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIq3cWZKSzVyPUCuNFA3OjJizszN	Ml;HV2FPT0WU
EM-2	MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LGU2lEPTB;MD6wNFYzOyEQvF2=	NX7jNFk3W0GQR1XS
D-283MED	NVnrNm9OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwMEC2NlQh\|ryP	NXrh[5dZW0GQR1XS
NCI-H1755	NFradHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7aWo5HUUN3ME2wMlAxPjJ2IN88US=>	NFnUUI1USU6JRWK=
KYSE-70	NYjmUm1kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYexd3gyUUN3ME2wMlAxPjJ2IN88US=>	M3\UOHNCVkeHUh?=
SW626	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jwdGlEPTB;MD6wNFYzPCEQvF2=	NYTSNY1bW0GQR1XS
WM-115	NWPhNotvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\rcmtKSzVyPUCuNFA3OjdizszN	NULpNolCW0GQR1XS
NB69	M1vQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XPZmlEPTB;MD6wNFYzQSEQvF2=	NYXFfllWW0GQR1XS
DOHH-2	MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwMEC2N{DPxE1?	MXHTRW5ITVJ?
MEL-JUSO	NILNTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwMEC2N\|kh\|ryP	NI\JbWFUSU6JRWK=
IGR-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fqcWlEPTB;MD6wNFY1OSEQvF2=	MULTRW5ITVJ?
ACN	MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\UTWM2OD1yLkCwOlQ1KM7:TR?=	MUnTRW5ITVJ?
KARPAS-45	NF3sUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYGx[oVCUUN3ME2wMlAxPjV{IN88US=>	MYPTRW5ITVJ?
HC-1	M4n4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlK0TWM2OD1yLkCwOlU3KM7:TR?=	M2XJUXNCVkeHUh?=
MZ2-MEL	NIHKSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfEOpJKSzVyPUCuNFA3PThizszN	Mn7WV2FPT0WU
NCI-H1355	MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwMEC2O\|kh\|ryP	Mor2V2FPT0WU
HuP-T4	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMEC2O\|kh\|ryP	MVjTRW5ITVJ?
AsPC-1	NVHMOlNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTtTWM2OD1yLkCwOlg{KM7:TR?=	NFm4OYlUSU6JRWK=
SCC-15	MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwMEC2PFkh\|ryP	Ml\5V2FPT0WU
CP50-MEL-B	M4j1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXHepRVUUN3ME2wMlAxPjl\|IN88US=>	NGrtWGVUSU6JRWK=
DMS-114	MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELkPG9KSzVyPUCuNFA3QTZizszN	MnOyV2FPT0WU
KYSE-520	M2mwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPCRpBKSzVyPUCuNFA4KM7:TR?=	MWXTRW5ITVJ?
NCI-H2228	NYjMeWxST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2K2[2lEPTB;MD6wNFczPSEQvF2=	Mm\DV2FPT0WU
COLO-829	NVTqW21lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTBwMEC3NlUh\|ryP	M2m2XnNCVkeHUh?=
NCI-H2052	NFHVSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7X[ZlKSzVyPUCuNFA4OjdizszN	MUTTRW5ITVJ?
HOP-92	MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFKxRmxKSzVyPUCuNFA4OyEQvF2=	M4TwWnNCVkeHUh?=
MDA-MB-231	NYTqe4RCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTmTWM2OD1yLkCwO\|Mh\|ryP	M1W5NXNCVkeHUh?=
SK-MEL-30	MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLCTWM2OD1yLkCwO\|MzKM7:TR?=	M1jIPHNCVkeHUh?=
NCI-H2087	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTBwMEC3OFgh\|ryP	NUO2S3VxW0GQR1XS
SW900	NYq3cGh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\hTWM2OD1yLkCwO\|U2KM7:TR?=	MXLTRW5ITVJ?
NCI-H358	NUTve\|BpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDQZXZGUUN3ME2wMlAxPzV6IN88US=>	NYHCeVVVW0GQR1XS
NCI-H2126	NUTvW5BnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NED6cmpKSzVyPUCuNFA4PzNizszN	NGXD[o5USU6JRWK=
TGBC24TKB	MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFX4eY5KSzVyPUCuNFA4QDFizszN	NEO5cJdUSU6JRWK=
786-0	M3;XVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\ENmlEPTB;MD6wNFc5PiEQvF2=	MVPTRW5ITVJ?
no-10	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonkTWM2OD1yLkCwO\|g5KM7:TR?=	MUTTRW5ITVJ?
SCH	NV\CU4tIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTGT3h6UUN3ME2wMlAxQDF6IN88US=>	M3H6fnNCVkeHUh?=
COLO-741	M3fJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzGVmlKSzVyPUCuNFA5OiEQvF2=	NInVNotUSU6JRWK=
NCI-H82	M3;mcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMEC4NlIh\|ryP	MmHaV2FPT0WU
MOLT-16	NGjWNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTBwMEC4Nlch\|ryP	MlvPV2FPT0WU
IST-MES1	NHHwUmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDYXopKSzVyPUCuNFA5PCEQvF2=	MlriV2FPT0WU
NCI-H1623	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILzWINKSzVyPUCuNFA5PTZizszN	NGfreW5USU6JRWK=
NCI-H1299	NYnUUmVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkO2TWM2OD1yLkCwPFU4KM7:TR?=	NInsdlJUSU6JRWK=
SNU-423	MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWW5ToN7UUN3ME2wMlAxQDV5IN88US=>	MmDLV2FPT0WU
ALL-PO	NWPUTm5oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\JeHBPUUN3ME2wMlAxQDZizszN	MVnTRW5ITVJ?
DK-MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{f1RmlEPTB;MD6wNFg3KM7:TR?=	NULONll3W0GQR1XS
LB1047-RCC	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwMEC4PEDPxE1?	NH6wNpVUSU6JRWK=
OMC-1	NGjXNHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTXTWM2OD1yLkCwPVA3KM7:TR?=	MkPwV2FPT0WU
TGBC1TKB	Mmj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTBwMEC5NUDPxE1?	MnfiV2FPT0WU
DBTRG-05MG	MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMEC5NVch\|ryP	MmPvV2FPT0WU
HPAF-II	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nmZWlEPTB;MD6wNFkzPiEQvF2=	M3u1S3NCVkeHUh?=
A204	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfodZlKSzVyPUCuNFA6OzRizszN	M{fSUHNCVkeHUh?=
TK10	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmK4TWM2OD1yLkCwPVc4KM7:TR?=	NY\JTGxnW0GQR1XS
BHT-101	NFPFSI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkW4TWM2OD1yLkCwPVgh\|ryP	M2flPXNCVkeHUh?=
SK-N-DZ	NV\yNJpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4O4RmlEPTB;MD6wNFk5OyEQvF2=	MlvWV2FPT0WU
ChaGo-K-1	Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XZ[2lEPTB;MD6wNFk5QCEQvF2=	MnnLV2FPT0WU
NCI-H661	MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIn5cXhKSzVyPUCuNFExODVizszN	NVnlT4ZUW0GQR1XS
AM-38	NUS3Xo91T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XZZ2lEPTB;MD6wNVAzPCEQvF2=	MXfTRW5ITVJ?
ML-2	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HiZmlEPTB;MD6wNVAzQSEQvF2=	MnnNV2FPT0WU
TCCSUP	NWD0bZhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\2TWM2OD1yLkCxNFM3KM7:TR?=	MW\TRW5ITVJ?
SW1990	M3viN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkC1TWM2OD1yLkCxNFQ4KM7:TR?=	MnTwV2FPT0WU
HCC1395	NX2xUZh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTSS44xUUN3ME2wMlAyODV4IN88US=>	NUj4RWRDW0GQR1XS
PANC-10-05	M1[5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDRXpBKSzVyPUCuNFExPTZizszN	MVnTRW5ITVJ?
CAKI-1	NV7MSndpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7ETWM2OD1yLkCxNFc{KM7:TR?=	MWLTRW5ITVJ?
HuP-T3	NVvFUGpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwMEGwO\|ch\|ryP	MYnTRW5ITVJ?
HT-1197	NYDXNmhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGS4TVVKSzVyPUCuNFExQDRizszN	M1XPTHNCVkeHUh?=
MOLT-13	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnHTWM2OD1yLkCxNFg3KM7:TR?=	MYPTRW5ITVJ?
NCI-H1563	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmeyTWM2OD1yLkCxNFg4KM7:TR?=	M4TJdnNCVkeHUh?=
NCI-N87	M3\kVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofmTWM2OD1yLkCxNFk{KM7:TR?=	NUDHXZNoW0GQR1XS
LB373-MEL-D	NIG4OnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrtTWM2OD1yLkCxNFk1KM7:TR?=	MYLTRW5ITVJ?
EFO-21	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwMEGxJO69VQ>?	MVjTRW5ITVJ?
LU-134-A	NVrtXJhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGSxTZRKSzVyPUCuNFEyODJizszN	MmfZV2FPT0WU
DU-145	M123bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPLTWM2OD1yLkCxNVA4KM7:TR?=	MmL3V2FPT0WU
SF295	M1PoRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwMEGxNlYh\|ryP	MlvCV2FPT0WU
ABC-1	NHTON\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmX3TWM2OD1yLkCxNVQ3KM7:TR?=	NHXBdIlUSU6JRWK=
TE-6	Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\h[mlEPTB;MD6wNVE1QCEQvF2=	NWnFNmhpW0GQR1XS
GAK	MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLuTWM2OD1yLkCxNVU5KM7:TR?=	MWfTRW5ITVJ?
LU-139	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwMEGxOlYh\|ryP	NGPMU4tUSU6JRWK=
EW-18	Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jVZmlEPTB;MD6wNVE3QSEQvF2=	M2XrfXNCVkeHUh?=
MSTO-211H	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHTTWM2OD1yLkCxNVc{KM7:TR?=	NVzWWFZkW0GQR1XS
KU812	NF7UbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwMEGxPVgh\|ryP	NWr0XY9jW0GQR1XS
NCI-H441	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{W5Z2lEPTB;MD6wNVE6QCEQvF2=	Mme1V2FPT0WU
LU-99A	M2izOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrqOIVDUUN3ME2wMlAyOiEQvF2=	MX;TRW5ITVJ?
NB10	M4r1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nrXGlEPTB;MD6wNVIxQSEQvF2=	NHX3SJBUSU6JRWK=
NCI-H1650	NXH2NnJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\HTWM2OD1yLkCxNlI6KM7:TR?=	NITm[XVUSU6JRWK=
YAPC	M{XxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3Se3FKSzVyPUCuNFEzOzdizszN	MkLxV2FPT0WU
HT55	NH;YO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwMEGyOFIh\|ryP	M{TlWXNCVkeHUh?=
NB7	NVLmN\|lyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LWUmlEPTB;MD6wNVI1OyEQvF2=	MnXLV2FPT0WU
NCI-H2030	M2DQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moq1TWM2OD1yLkCxNlU1KM7:TR?=	NFnSRWdUSU6JRWK=
EW-22	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTBwMEGyOVYh\|ryP	MXfTRW5ITVJ?
UMC-11	NWXNXplMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4ezbWlEPTB;MD6wNVI5OyEQvF2=	M1yxOHNCVkeHUh?=
MKN7	NELE[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;JOXpIUUN3ME2wMlAyOjh\|IN88US=>	MlPVV2FPT0WU
OE33	MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwMEGzJO69VQ>?	NYT5WldyW0GQR1XS
SK-LU-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwMEGzNlQh\|ryP	NHrkUWVUSU6JRWK=
LAMA-84	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHlOZQ6UUN3ME2wMlAyOzJ6IN88US=>	NUnCUYxSW0GQR1XS
IA-LM	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\aSIpKSzVyPUCuNFE{OyEQvF2=	NVPxUFhLW0GQR1XS
HuH-7	M{jISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7KdmxKSzVyPUCuNFE{PTRizszN	M{PUXXNCVkeHUh?=
J82	MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnO[4tKSzVyPUCuNFE{QSEQvF2=	NFTGbpdUSU6JRWK=
CFPAC-1	MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjne5BKSzVyPUCuNFE1ODZizszN	MofSV2FPT0WU
MN-60	M2rtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HjdWlEPTB;MD6wNVQzQSEQvF2=	MV7TRW5ITVJ?
A704	NGDyNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnkS2VKSzVyPUCuNFE1OzhizszN	MlL2V2FPT0WU
SW684	MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDPfotKSzVyPUCuNFE1PTJizszN	MVLTRW5ITVJ?
NOS-1	MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorOTWM2OD1yLkCxOFYh\|ryP	MnnjV2FPT0WU
U-118-MG	NYXKOId3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPsc3A4UUN3ME2wMlAyPDdizszN	MnHTV2FPT0WU
NCI-H596	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrqeotpUUN3ME2wMlAyPDd5IN88US=>	MX;TRW5ITVJ?
RS4-11	M3KySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HReGlEPTB;MD6wNVUyPiEQvF2=	MUDTRW5ITVJ?
KP-N-YS	NInmVnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnr0TWM2OD1yLkCxOVI{KM7:TR?=	NF72Z2NUSU6JRWK=
MS-1	M3;nN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwMEG1OFUh\|ryP	NHe4PWtUSU6JRWK=
A101D	NIjud3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fKUWlEPTB;MD6wNVU1QSEQvF2=	NYi5[YszW0GQR1XS
DSH1	NXq1T4x3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3BdlJJUUN3ME2wMlAyPiEQvF2=	MYfTRW5ITVJ?
CAS-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonKTWM2OD1yLkCxOlA6KM7:TR?=	MkHlV2FPT0WU
NCI-H2347	NWjPeYdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMEG2N\|Yh\|ryP	MlzKV2FPT0WU
T-24	MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfTOo9KSzVyPUCuNFE4ODVizszN	MUjTRW5ITVJ?
MEG-01	NGrkSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHDTWM2OD1yLkCxO\|M4KM7:TR?=	NHvLemxUSU6JRWK=
NCI-H2291	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\yTWM2OD1yLkCxPFM5KM7:TR?=	M3LJXHNCVkeHUh?=
SW872	MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXYSY03UUN3ME2wMlAyQDZ5IN88US=>	M3LDN3NCVkeHUh?=
no-11	NF;jfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIKxbI9KSzVyPUCuNFE5QDdizszN	MWnTRW5ITVJ?
NB5	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwMEG4PVEh\|ryP	NX7zeXl2W0GQR1XS
MZ7-mel	NHrsVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzkTWM2OD1yLkCxPVM1KM7:TR?=	Moj4V2FPT0WU
BT-474	M3GwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTXUG5CUUN3ME2wMlAyQTR\|IN88US=>	NYXoeXBlW0GQR1XS
OAW-28	NYXib3gxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2j2[2lEPTB;MD6wNVk2PiEQvF2=	Ml3uV2FPT0WU
ES6	NUL0eodET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPvTWM2OD1yLkCyNFA5KM7:TR?=	NEGwe\|dUSU6JRWK=
PC-3	NYLYeGxyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1ziZWlEPTB;MD6wNlA{PiEQvF2=	MX;TRW5ITVJ?
COR-L88	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2L6[mlEPTB;MD6wNlA2PCEQvF2=	NEnKc\|lUSU6JRWK=
D-392MG	MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\jSZZKSzVyPUCuNFIxPjhizszN	NIH1PXJUSU6JRWK=
LB2518-MEL	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwMEKxOlEh\|ryP	NYn3PFJ6W0GQR1XS
LoVo	M{nBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLmO4Y5UUN3ME2wMlAzOTd{IN88US=>	M3HuVXNCVkeHUh?=
HCC1954	M3HISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fiT2lEPTB;MD6wNlE6OiEQvF2=	MWjTRW5ITVJ?
COLO-792	MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwMEKxPVYh\|ryP	MYrTRW5ITVJ?
KLE	NEjNNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrNWI9KSzVyPUCuNFI{OjNizszN	MkfrV2FPT0WU
MDA-MB-157	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoP5TWM2OD1yLkCyN\|Q6KM7:TR?=	NF7IdVRUSU6JRWK=
PANC-08-13	M2XO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLncldKSzVyPUCuNFI1PjVizszN	MlL2V2FPT0WU
NCI-H727	M1XWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljzTWM2OD1yLkCyOFc1KM7:TR?=	MUHTRW5ITVJ?
NCI-H1155	MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXlXYdKSzVyPUCuNFI1PzdizszN	Mlz3V2FPT0WU
GCIY	NH7pd\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;zZWlEPTB;MD6wNlUxOiEQvF2=	NI\iNG5USU6JRWK=
MKN1	MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2K5bWlEPTB;MD6wNlU4PiEQvF2=	MVjTRW5ITVJ?
NCI-H1092	M1Xr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwMEK2OVQh\|ryP	M4j1VHNCVkeHUh?=
RMG-I	NXu2VJc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HmVmlEPTB;MD6wNlch\|ryP	MoHHV2FPT0WU
NB12	MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jUeWlEPTB;MD6wNlczKM7:TR?=	Mny3V2FPT0WU
RCM-1	M1HVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljKTWM2OD1yLkCyPFE6KM7:TR?=	MkjDV2FPT0WU
C3A	M1W5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUOzbFZzUUN3ME2wMlAzQDJ{IN88US=>	MUnTRW5ITVJ?
NCI-H747	NWLEVZZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLDUpNKSzVyPUCuNFI5OzdizszN	MmrTV2FPT0WU
LB771-HNC	M1\ZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jYeGlEPTB;MD6wNlg{PyEQvF2=	MXzTRW5ITVJ?
EW-13	NWHlTow4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1r6NmlEPTB;MD6wNlkxPCEQvF2=	MkLkV2FPT0WU
CAL-72	NVfoXYdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3BN4ZKSzVyPUCuNFI6OThizszN	M3vCdHNCVkeHUh?=
HH	M3fpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYH3VHM{UUN3ME2wMlAzQTl6IN88US=>	NUXVZlVRW0GQR1XS
UACC-257	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHGUmJKSzVyPUCuNFMxOyEQvF2=	NXn5[3RyW0GQR1XS
OAW-42	NIGzd\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDPT29KSzVyPUCuNFMxOyEQvF2=	MU\TRW5ITVJ?
CAPAN-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHixZndKSzVyPUCuNFMxPTJizszN	MXHTRW5ITVJ?
SNU-C2B	NWOyZY1VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwMEOwOlMh\|ryP	MXHTRW5ITVJ?
NKM-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vhS2lEPTB;MD6wN\|E3QSEQvF2=	NYHkdVY5W0GQR1XS
GR-ST	NXzFZmFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFP1[WpKSzVyPUCuNFMyQDVizszN	NGTBN5VUSU6JRWK=
SW1463	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\SRohKSzVyPUCuNFM{OzdizszN	MVfTRW5ITVJ?
MEL-HO	NU\DdnExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PzPWlEPTB;MD6wN\|QzOSEQvF2=	M3fkdXNCVkeHUh?=
NCI-H2342	NH7rWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfLXXJKSzVyPUCuNFM3OzNizszN	MnrwV2FPT0WU
ACHN	NUPMNZRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jURmlEPTB;MD6wN\|cyKM7:TR?=	NUi3W2NwW0GQR1XS
RH-18	NHixc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTCOGJZUUN3ME2wMlA{PzZ\|IN88US=>	NF3DZ5pUSU6JRWK=
HCC2218	MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7ibHlKSzVyPUCuNFM4QSEQvF2=	MVvTRW5ITVJ?
OS-RC-2	M3TLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwMEO4Olkh\|ryP	NWHWeWVEW0GQR1XS
KP-N-YN	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1WyT2lEPTB;MD6wN\|g4PiEQvF2=	MmPTV2FPT0WU
COLO-668	NF;3V3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nFdWlEPTB;MD6wN\|g5PyEQvF2=	MXvTRW5ITVJ?
LU-65	NHjTXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGKzPJpKSzVyPUCuNFM6ODRizszN	M1;YTnNCVkeHUh?=
NB6	M1TOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkP6TWM2OD1yLkCzPVUzKM7:TR?=	NIH2Vm1USU6JRWK=
HT	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPneJNKSzVyPUCuNFQxODdizszN	NWTVNGRjW0GQR1XS
COLO-684	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWq1OlFMUUN3ME2wMlA1ODl3IN88US=>	NGCz[m9USU6JRWK=
NCI-H1693	NYP0Z2hqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljrTWM2OD1yLkC0N\|A2KM7:TR?=	MXjTRW5ITVJ?
LAN-6	NGXTXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XUTmlEPTB;MD6wOFM{PSEQvF2=	Moi3V2FPT0WU
MDA-MB-175-VII	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYqwVYdCUUN3ME2wMlA1PDF5IN88US=>	MWnTRW5ITVJ?
KMOE-2	NVriVWlVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfK[oxxUUN3ME2wMlA1PDZ7IN88US=>	MUHTRW5ITVJ?
DMS-79	NIK2NHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwMES1O\|kh\|ryP	M{nmWXNCVkeHUh?=
MHH-NB-11	NFi2N\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fVfWlEPTB;MD6wOFYyPCEQvF2=	M4HrS3NCVkeHUh?=
NCI-H69	NGG2b4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPO[JVVUUN3ME2wMlA1QDR7IN88US=>	MmTsV2FPT0WU
KE-37	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnOTWM2OD1yLkC1NFEh\|ryP	MYHTRW5ITVJ?
Ramos-2G6-4C10	M3fXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwMEWwOlch\|ryP	NVHMenZ1W0GQR1XS
NCI-H1793	M{nlcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMEWwPVMh\|ryP	MWfTRW5ITVJ?
HT-1376	NV[3UFJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;mT2lEPTB;MD6wOVE5PiEQvF2=	M2Cxd3NCVkeHUh?=
EKVX	M{TDTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPldVdIUUN3ME2wMlA2Ozh2IN88US=>	NUjxZnVKW0GQR1XS
Capan-2	MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rLOGlEPTB;MD6wOVM6PiEQvF2=	NFHOdI5USU6JRWK=
DoTc2-4510	MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmW1TWM2OD1yLkC1OFQ3KM7:TR?=	MnTJV2FPT0WU
UACC-893	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jS[mlEPTB;MD6wOVQ3OiEQvF2=	NIDJ[YhUSU6JRWK=
SK-MEL-3	NXLMe40xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHjOWdKSzVyPUCuNFU4QDhizszN	NI\QU3BUSU6JRWK=
SK-MEL-1	NILSclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvJUY5KSzVyPUCuNFU5KM7:TR?=	MUTTRW5ITVJ?
SW948	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwMEW5PVYh\|ryP	M1nm[HNCVkeHUh?=
P30-OHK	NWHqRmk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\KNmlEPTB;MD6wOlE3PyEQvF2=	NV\KfppJW0GQR1XS
NH-12	Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLFUIlmUUN3ME2wMlA3OjR2IN88US=>	NIf0PHJUSU6JRWK=
KU-19-19	NEXY[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;OTWM2OD1yLkC2N\|YyKM7:TR?=	MYTTRW5ITVJ?
A431	MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXLXlBKSzVyPUCuNFY{PzRizszN	M3KxWHNCVkeHUh?=
NCI-H2405	MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnITWM2OD1yLkC2N\|g{KM7:TR?=	MnXiV2FPT0WU
KARPAS-299	NHPOdGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwME[1PFIh\|ryP	M3HPV3NCVkeHUh?=
BALL-1	NHfPNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1i1R2lEPTB;MD6wOlY4PCEQvF2=	MW\TRW5ITVJ?
KURAMOCHI	NWTJWplMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\TS3FKSzVyPUCuNFcxPzNizszN	NUPRSot4W0GQR1XS
LS-1034	NEDDNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTBwMEezOlkh\|ryP	NF3McGlUSU6JRWK=
MFE-280	NWL1PHM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjRV5pKSzVyPUCuNFc2OzZizszN	NGG2SZFUSU6JRWK=
HOP-62	NEHBVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFq1fItKSzVyPUCuNFc3PzZizszN	NFzKcJlUSU6JRWK=
KG-1	NU\yPVhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1T4cWlEPTB;MD6wO\|c5PyEQvF2=	NFfFXJBUSU6JRWK=
CW-2	NXvQOXlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjqbHVCUUN3ME2wMlA4QDN{IN88US=>	M1K2T3NCVkeHUh?=
SW837	NV;jN5NrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHmwZo1KSzVyPUCuNFg{PDJizszN	NW\rSGVRW0GQR1XS
MFH-ino	NH[4Z5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PYN2lEPTB;MD6wPFUxOSEQvF2=	NGL3O2ZUSU6JRWK=
HCC1419	NVXHboZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwMEi5PFch\|ryP	MoLDV2FPT0WU
HMV-II	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfDOWJ5UUN3ME2wMlA6ODFizszN	MYjTRW5ITVJ?
BEN	MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXlS\|ZzUUN3ME2wMlA6Ozh3IN88US=>	NWPvWY1EW0GQR1XS
SK-N-FI	MojDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPk[mh1UUN3ME2wMlA6PTV4IN88US=>	MXTTRW5ITVJ?
JVM-2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;xTWM2OD1yLkC5O\|E3KM7:TR?=	NULxOItDW0GQR1XS
CAL-54	NHTXOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrWV2NKSzVyPUCuNVAxPCEQvF2=	NFzFXllUSU6JRWK=
T84	NVzHfXJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;0Ull1UUN3ME2wMlExQTV{IN88US=>	MXPTRW5ITVJ?
SHP-77	NFK0[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDtTWM2OD1yLkGxOlQyKM7:TR?=	MkfDV2FPT0WU
G-361	NF3qTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwMUKzNlQh\|ryP	NH\wRnJUSU6JRWK=
Calu-3	NYK5eXJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTWTWM2OD1yLkGzPFE3KM7:TR?=	NEHETIVUSU6JRWK=
HCC1937	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfYSHE2UUN3ME2wMlE1QTN5IN88US=>	M3PX[XNCVkeHUh?=
KM-H2	NGHzPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33hUGlEPTB;MD6xOVAyKM7:TR?=	NUDI[FhbW0GQR1XS
769-P	NHryPZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjvNYFyUUN3ME2wMlE2QDR\|IN88US=>	M{XYdXNCVkeHUh?=
NCI-H1304	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPPTWM2OD1yLkG2NFYyKM7:TR?=	MoT3V2FPT0WU
D-542MG	MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLrTWM2OD1yLkG2Nlc5KM7:TR?=	NFriUndUSU6JRWK=
ATN-1	NVThTYhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4X6T2lEPTB;MD6xO\|Q1OSEQvF2=	MVrTRW5ITVJ?
NCI-H2029	MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDkbJYzUUN3ME2wMlIxOjR\|IN88US=>	M1\ZNXNCVkeHUh?=
ZR-75-30	NWTBfFZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDZXWNKSzVyPUCuNlA3PDNizszN	MmKwV2FPT0WU
SW1116	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXrcmV4UUN3ME2wMlIyOTF5IN88US=>	NHSyRmdUSU6JRWK=
CCRF-CEM	M{fWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjibFFnUUN3ME2wMlI4PjF2IN88US=>	NUf4NphWW0GQR1XS
LU-135	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYj3TmdSUUN3ME2wMlI4PzN7IN88US=>	NEmwWFBUSU6JRWK=
MC116	M1vISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HZZ2lEPTB;MD6yPFMxQSEQvF2=	MXPTRW5ITVJ?
LS-513	MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moi0TWM2OD1yLkK4O\|c{KM7:TR?=	Ml;zV2FPT0WU
NCI-H630	NUmwVpF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mon1TWM2OD1yLkK5N\|c3KM7:TR?=	NFG0VmJUSU6JRWK=
L-428	MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETiTJhKSzVyPUCuNlk5QDNizszN	MoS4V2FPT0WU
UM-UC-3	NYHVOVNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYD4fGRvUUN3ME2wMlMyOjlzIN88US=>	MXLTRW5ITVJ?
NCI-H1838	M4j3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDVTZRKSzVyPUCuN\|E4QDRizszN	MWHTRW5ITVJ?
HEL	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwM{KyOEDPxE1?	MmfQV2FPT0WU
OCI-AML2	MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjmTWM2OD1yLkOyNlk5KM7:TR?=	MV7TRW5ITVJ?
A3-KAW	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jtfmlEPTB;MD6zN\|Q4PyEQvF2=	M37xUnNCVkeHUh?=
IGROV-1	MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDXTWM2OD1yLkOzO\|U2KM7:TR?=	MX7TRW5ITVJ?
Mo-T	NEXtZ\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPIPFhLUUN3ME2wMlM{QDV\|IN88US=>	M3jxfXNCVkeHUh?=
HDLM-2	NWHUNYl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfac4lXUUN3ME2wMlM{QSEQvF2=	M1fuUHNCVkeHUh?=
HCC1569	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXaWFhYUUN3ME2wMlM1OzB7IN88US=>	M1T0PXNCVkeHUh?=
COLO-678	M1P1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3GxZ2lEPTB;MD6zO\|AxOiEQvF2=	M1TpS3NCVkeHUh?=
COR-L105	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jH[GlEPTB;MD6zO\|k{KM7:TR?=	MVrTRW5ITVJ?
SK-MEL-24	NIG2SGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrpUGZKSzVyPUCuN\|g{QDJizszN	M1W4WHNCVkeHUh?=
COLO-320-HSR	NI\wc\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlWyTWM2OD1yLkSzPVc3KM7:TR?=	MlzTV2FPT0WU
C8166	M1Ht[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvDTWM2OD1yLkS5NFI{KM7:TR?=	Ml;5V2FPT0WU
COLO-679	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3tclNOUUN3ME2wMlYzOTd{IN88US=>	M2rNRXNCVkeHUh?=
TE-12	M1fYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfXTWM2OD1yLk[1N\|k1KM7:TR?=	NXnXdnNzW0GQR1XS
HAL-01	NXL1W5RlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1Ptc2lEPTB;MD62OlIzKM7:TR?=	NFXWbGxUSU6JRWK=
H-EMC-SS	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fsOGlEPTB;MD63NFU1PiEQvF2=	MnT3V2FPT0WU
SNU-449	NFfxXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TZNmlEPTB;MD63Nlc1QCEQvF2=	NFP6dnBUSU6JRWK=
C32	NVrRO2pIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDCZ49sUUN3ME2wMlc1OTF{IN88US=>	NGrRN4hUSU6JRWK=
K-562	NWXDfVZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHG[\|Q6UUN3ME2wMlc4ODJ2IN88US=>	NFH2OGNUSU6JRWK=
DJM-1	NH23U2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfZW3NsUUN3ME2wMlc5PzhzIN88US=>	NYq3OI5FW0GQR1XS
RCC10RGB	NIroOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwN{mxPFMh\|ryP	M{PEUXNCVkeHUh?=
CAL-85-1	M4Xxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1Hj[2lEPTB;MD65NFch\|ryP	NFHzSoRUSU6JRWK=
NY	NX\0NZRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLKSmNKSzVyPUCuPVM{PTJizszN	M1\MZ3NCVkeHUh?=
NCI-H1993	NV30blExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTFwMUmyPFkh\|ryP	MU\TRW5ITVJ?
SK-OV-3	M3XERWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XSVmlEPTB;MT6yNlA5QSEQvF2=	NX7iWHE5W0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PIM1; PubMed: 18426800 J Biol Chem Cells were treated with 100 nm docetaxel for the indicated times. PIM1 and β-ACTIN proteins were analyzed by immunoblot analysis. One of three similar blots is shown. Ratio, ratio of PIM1/β-ACTIN from pooled densitometry data from three separate experimen䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ cyclin B; PubMed: 18426800 J Biol Chem Immunoblot analysis of cyclin B1 and PIM1 expression after docetaxel 10 nm (left) or 100 nm (right) treatment at various time points. pSTAT3 / STAT3 ; PubMed: 18426800 J Biol Chem Immunoblots of RWPE-2 cells treated with 100 nm docetaxel for the indicated time. p-p53 / p53; PubMed: 22996738 Prostate C4-2 cells were treated with 5 nM docetaxel, the whole cell lysates were collected at different time points and subjected to Western blot.	18426800 22996738
Immunofluorescence	α-tubulin; PubMed: 27177833 Exp Cell Res Noscapine has no effect on gross microtubule polymerization state but noscapine pre-sensitization followed by docetaxel treatment stabilizes microtubules, hence inhibits cell proliferation. TNBC cells were treated with noscapine (4 µM) or docetaxel (0.4 µ䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뾠Ղ䐺痖暼瘿뾠Ղᾰƌ 뾠ՂÐ㺣痖뾠Ղ𢡄뾤Ղ䀷痗뾤Ղ౴뾤Ղ㵶痗뾤Ղ뺖᎒泌Itemｾ᎒Count﫨呂뿔Ղ猴፲뾤Ղ፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄堚Ҕ齃礤v�堞ﻮ᎒猢Wｾ᎒䨼Ą鹿齃殺獸W戀醙 cleaved PARP / cleaved caspase-3; PubMed: 21087597 Biochem Pharmacol Immunofluorescence images of PC-3 cells treated with the docetaxel and EM011 schedule treatment. Cells were pretreated with docetaxel for 12 h before addition of EM011 and were fixed at 48 h post docetaxel treatment compared to treatment with EM011 (10 μM䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋à Acetylated tubulin ; PubMed: 18426800 J Biol Chem Immunofluorescence of acetylated tubulin in cells treated with DMSO, 30 nM laulimalide and 30 nM docetaxel for 2.5 h. Tubulin shown in green and DAPI in blue, and the white arrow indicates microtubule bundling. Scale bar represents 10 μm. SQSTM1 / LAMP1; PubMed: 29795139 Cell Death Dis AGS cells were treated with docetaxel (10 nM) for 12 h. After immunostaining with SQSTM1 (Alexa Fluor 488, green) and LAMP1 (Alexa Fluor 594, red), cells were examined by fluorescence microscopy (scale bar 20 μm). The colocalization of SQSTM1and LAMP1 was䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ	27177833 21087597 18426800 29795139
Growth inhibition assay	Cell viability ; PubMed: 22996738 Prostate Docetaxel inhibits the growth of LNCaP, C4-2, DU145, and PC3 prostate cancer cells. Cells were plated in 12-well plates and treated with different concentrations of docetaxel. The cell number was counted after 24 hr.	22996738

In vivo

Docetaxel (33 mg/kg/dose, given i.v. every 4 days for 3 injections) results in a tumor growth delay of 19.3 days in M2OL2 colon xenografts. Docetaxel also shows great antitumor activities in MX-1, SK-MEL-2, LX-1 and OVCAR-3 xenografts. Docetaxel inhibits the angiogenic response to fibroblast growth factor 2 with IC 50 of 5.4 mg/kg when injected twice weekly over a 14-day period, and angiogenesis is completely blocked in mice that receives 10 mg/kg Docetaxel. Docetaxel has selectivity for endothelial cell migration and/or microvessel formation because infiltration of inflammatory cells into the Matrigel plug is much less sensitive to inhibition by Docetaxel. ^[7]

Protocol

Cell Research:^[5]

- Collapse

Cell lines: Human gastric cancer cell lines MKN-28
Concentrations: 6 nM
Incubation Time: 3 days
Method: 2000 cells in 180 μL of medium are seeded in a 96-well plate, and 20 μL of drug solution is simultaneously added in triplicate to each well. The plate is incubated for 3 days at 37°C in a humidified atmosphere of 5% CO₂. On day 3, 25 μL of MTT reagent is added to each well. After 4 h of incubation, the medium is removed by aspiration. 0.2 mL of dimethylsulphoxide (DMSO) is added to each well and thoroughly mixed by using a mechanical plate mixer to dissolve the resulting MTT-formazan crystals. Absorbance at 540 nm (OD) is measured by a reader.
(Only for Reference)

Animal Research:^[6]

- Collapse

Animal Models: Human colon carcinomas xenografts CX-1
Formulation: 50 mg/mL stock solution in ethanol by adding an equal volume of polysorbate 80 and diluting with 5% dextrose in water to the final volume
Dosages: 33 mg/kg
Administration: i.v. every 4 days for 3 injections
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (123.78 mM)
	Ethanol	53 mg/mL warmed (65.6 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Docetaxel SDF

Molecular Weight	807.88
Formula	C₄₃H₅₃NO₁₄
CAS No.	114977-28-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	RP56976, NSC 628503
Smiles	CC(=O)OC12COC1CC(O)C3(C)C2C(OC(=O)C4=CC=CC=C4)C5(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)C6=CC=CC=C6)C(=C(C(O)C3=O)C5(C)C)C

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04113005	Not yet recruiting	Drug: Desmopressin	Castrate Resistance Prostate Cancer	Sunnybrook Health Sciences Centre\|Sunnybrook Research Institute	October 1 2019	Early Phase 1
NCT03700099	Recruiting	Drug: Docetaxel\|Drug: Enzalutamide	Prostate Cancer\|Castration-resistant Prostate Cancer	Instituto do Cancer do Estado de São Paulo\|Astellas Pharma Inc	September 3 2019	Phase 2
NCT04067713	Recruiting	--	Metastatic Prostate Cancer	University College London\|Epic Sciences	September 20 2019	--
NCT03976375	Recruiting	Biological: Pembrolizumab\|Drug: Lenvatinib\|Drug: Docetaxel	Metastatic Non-Small Cell Lung Cancer	Merck Sharp & Dohme Corp.\|Eisai Inc.	June 26 2019	Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

TAI-1 ^New

TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Docetaxel Trihydrate ^New

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Combretastatin A4 ^New

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with K_d of 0.4 μM.Phase 3.
Paclitaxel

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Vincristine sulfate

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Nocodazole

Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole improves the CRISPR-mediated HDR efficiency and has an additive effect on enhancing precise genome editing.
Vinorelbine Tartrate

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
Cabazitaxel

Cabazitaxel is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide.

Features:A semi-synthetic derivative of a natural taxoid.
Patupilone (Epothilone B)

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC_0.01 of 1.8 μM. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Docetaxel